Platelet proteomic signatures of amyloid β-positive mild cognitive impairment and Alzheimer's disease - PubMed
8 hours ago
- #Biomarkers
- #Proteomics
- #Neurodegeneration
- Early detection of Alzheimer's disease (AD) is crucial for preventing progression.
- Platelets are a promising peripheral source for AD diagnosis, but proteomic biomarkers for mild cognitive impairment (MCI) and AD related to amyloid β (Aβ) deposition need further exploration.
- The study compared four groups: subjective memory impairment (SMI), MCI without Aβ deposition (MCI-A(+)), MCI with Aβ deposition (MCI-A(-)), and AD, using platelet protein profiling via LC-MS/MS.
- Among 4,524 detected proteins, unique and overlapping differentially expressed proteins were identified in MCI-A(+), MCI-A(-), and AD compared to SMI.
- Hierarchical clustering revealed seven distinct proteomic alteration patterns across groups.
- Functional analyses linked clusters to processes like platelet activation, AD, and apoptotic signaling pathways.
- Upregulated proteins in MCI-A(-) and AD were associated with endomembrane system organization.
- Specific proteins (ATP6V0C, AP4B1, RAB2B, PSMD9, FKBP1B, mTOR) were highlighted as potential molecular targets for predicting AD in the MCI stage with Aβ deposition.